Press Release on the Financial Results of the Company for the quarter ended June 30, 2026

August 5, 2026 BSE Limited The National Stock Exchange of India Ltd Phiroze Jeejeebhoy Towers, Exchange Plaza, 25th Floor, Dalal Street, Bandra Kurla Complex Mumbai – 400 001 Bandra (E), Mumbai – 400 001 Scrip Code: 524558 Scrip Code: NEULANDLAB; Series: EQ Dear Sir/Madam, Sub: Press Release Pursuant to Regulation 30 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, we are enclosing Press Release on the Financial Results of the Company for the quarter ended June 30, 2026. The Press Release is also being uploaded on the website of the Company at www.neulandlabs.com This is for your information and records. Yours sincerely, For Neuland Laboratories Limited Sarada Bhamidipati Company Secretary Encl: As above Neuland Q1FY27 Total income at Rs.650.1 crore; EBITDA at Rs.231.1 crore Hyderabad, India, August 5, 2026 – Neuland Laboratories Limited (NLL) (NSE: NEULANDLAB; BSE:524558), a pharmaceutical manufacturer providing active pharmaceutical ingredients (APIs), complex intermediates and custom manufacturing solutions services to customers located in around 80 countries, today announced financial results for the quarter ended June 30, 2026. Commenting on the performance Mr. Saharsh Davuluri, Chief Executive Officer and Managing Director, Neuland Laboratories added “Q1 FY27 was broadly in line with our expectations with encouraging performance from both CMS & GDS businesses and represents a good start to the year. While Commercial Products contributed to most of the revenue, we are seeing exciting developments in terms of the pipeline projects. The depth of customer conversations today is significantly stronger, and we are increasingly engaging on broader capability-led discussions rather than individual projects alone. Internally our focus now is on ensuring that we deliver consistently, build customer confidence and establish the foundation for long- term partnerships. Even as we have invested significantly over the last three years and all our significant Capex projects are proceeding according to plan, I believe the intensity of our investments will further increase based on the opportunities that available to us.” Financial Summary Rs. crore Particulars Q1FY27 Q1FY26 YoY (%) Q4FY26 QoQ (%) Total Income 650.1 300.6 116.3% 788.7 -17.6% EBITDA 231.1 42.1 448.2% 319.4 -27.6% EBITDA Margin 35.5% 14.0% 2150 bps 40.5% -500 bps Profit Before Tax 197.5 17.4 1036.7% 287.0 -31.2% PBT Margin 30.4% 5.8% 2460 bps 36.4% -601 bps Profit After Tax 147.4 13.7 975.0% 212.5 -30.6% PAT Margin 22.7% 4.6% 1811 bps 26.9% -423 bps EPS (Rs.) 114.9 10.7 975.0% 165.6 -30.6% WWW.NEULANDLABS.COM | BSE: 524558 NSE: NEULANDLAB | BLOOMBERG: NLL: IN |SECTOR: PHARMACEUTICALS Q1 FY27 Earnings Call The company will conduct a one-hour Earnings call at 17:30 hrs. IST on Wednesday, August 5, 2026 where the management will discuss the Company’s performance and answer questions from participants. To participate in this conference call, please register on the link below: Diamond Pass Registration Link Webcast Link Please note that the transcript of the conference call will be uploaded on the company website in due course. About Neuland Laboratories Limited For over 4 decades, Neuland Labs has been at the forefront of manufacturing APIs through its cGMP manufacturing facilities, working with customers in close to 80 countries. Neuland Labs has developed more than 300 processes and 100 APIs and has filed around 1010+ Regulatory filings across the US (75 active US DMFs), the European Union (EU) and other geographies. Its record of quality manufacturing and reliability is highlighted by cGMP certifications that include the U.S. FDA, TGA (Australia), EDQM (EU), German Health Authority, ANVISA (Brazil), EMA (EU), Cofepris (Mexico), KFDA (Korea), PMDA (Japan), CFDA (China), FSI “SID & GP” Russia, Health Canada, ISO 9001, ISO14001, OHSAS18001 and ISO 27001. For more information, visit www.NeulandLabs.com. If you have any questions or require further information, please feel free to contact IR Department at Neuland Tel: +91 40 6761 1600 Email: ir@neulandlabs.com Runjun Jain / Minakshi Machutre EY IR Email: Runjhun.Jain1@in.ey.com / Minakshi.machutre@in.ey.com